•
-
Biomanufacturing
Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS
Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.
Featuring

Babu Raman
Corteva Agriscience
External Collab. Portfolio Leader

Colby Adolph
Evonik
Sales Director
Fermentation scale-up connector: turning prototypes into manufacturable reality

Ling Li
ADM
Dir. Market Dev., Prec. Ferm.
Precision fermentation dealmaker bridging startups, scale, and brands

Eric Lee
Primient
Director, B&D - Fermentation

Blake Simmons
LBNL
Dir. Bio. Sys & Engg
Ionic-liquid biomass deconstruction pioneer; National Academy of Inventors fellow.

Jamie Bacher
Huxley Project
Principal
Ag-biotech veteran guiding tech to market.
•
-
Biomanufacturing
Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS
Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.
Featuring

Babu Raman
Corteva Agriscience
External Collab. Portfolio Leader

Colby Adolph
Evonik
Sales Director
Fermentation scale-up connector: turning prototypes into manufacturable reality

Ling Li
ADM
Dir. Market Dev., Prec. Ferm.
Precision fermentation dealmaker bridging startups, scale, and brands

Eric Lee
Primient
Director, B&D - Fermentation

Blake Simmons
LBNL
Dir. Bio. Sys & Engg
Ionic-liquid biomass deconstruction pioneer; National Academy of Inventors fellow.

Jamie Bacher
Huxley Project
Principal
Ag-biotech veteran guiding tech to market.
SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.
The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.
Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt
Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg
Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas
Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville
Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai
Co-founder
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira
Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek
CEO





















































































































